Skip to main content
Amgen logo
AMGN.NASDAQ
Amgen
Healthcare · Drug Manufacturers - General

Biotechnology pioneer discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses.

HQ: United StatesListed: United States

Profile & Fundamentals

Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Amgen.

Profile & Fundamentals

Amgen Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

AMGN.NASDAQ

Company profile record

Amgen Inc

Common Stock · Healthcare · Drug Manufacturers - General

Official website

Company

Company / asset
Amgen Inc
Security type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - General
HQ
🇺🇸 United States
Head office
One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Leadership & scale

Chief executive
Mr. Robert A. Bradway
CEO year born
1963
Full-time employees
31.5K
Fiscal year end
December
IPO date
1983-06-17

Fundamentals snapshot

Updated 2026-07-27
Market Cap
USD 209.5B
P/E
26.9x
Revenue (Q1 26)
USD 8.6B
Profit (Q1 26)
USD 1.8B
Dividend Yield
1.8%
Revenue (FY 25)
USD 36.7B
Shares in public float
538.2M
Insider ownership
0.22%

Reporting & identifiers

Symbol
AMGN.NASDAQ
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US0311621009
Asset ID
equity_3f8ad8b5-f4b0-5cb9-9c03-b91a45b1c70a

Ownership

Shares Outstanding

Latest: 544.0M | Max: 1.1B | Min: 539.0M

Shares Outstanding
1.4B1.0B688.0M344.0M0.00
'07
'09
'11
'13
'15
'17
'19
'21
'23
'25
'26

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.